Do you try to incorporate mFOLFIRINOX in total neoadjuvant therapy for rectal cancer?

PRODIGE 23 study is an open-label, randomized phase 3 study (Conroy et al., PMID 33862000).

Locally advanced rectal cancer patients (cT3 or cT4 M0) were randomized to either the study arm (mFOLFIRINOX X 3 months, chemoradiation, TME, FOLFOX X 3 months) or the standard arm (chemoradiation followed by...

Dr. @Dr. First Last's answer is very reasonable. In general, we do not routinely utilize mFOLFIRINOX as part of TNT at our center. At this point, it is not clear if intensification of consolidation chemotherapy with the addition of irinotecan in TNT improves rates of cCR compared to standard FOLFOX/...